Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.

Agoston GE, Shah JH, Lavallee TM, Zhan X, Pribluda VS, Treston AM.

Bioorg Med Chem. 2007 Dec 15;15(24):7524-37. Epub 2007 Sep 14.

PMID:
17910916
2.

Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.

Agoston GE, Shah JH, Suwandi L, Hanson AD, Zhan X, LaVallee TM, Pribluda V, Treston AM.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6241-4. doi: 10.1016/j.bmcl.2009.08.020. Epub 2009 Aug 8.

PMID:
19782564
3.

Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.

Shah JH, Agoston GE, Suwandi L, Hunsucker K, Pribluda V, Zhan XH, Swartz GM, LaVallee TM, Treston AM.

Bioorg Med Chem. 2009 Oct 15;17(20):7344-52. doi: 10.1016/j.bmc.2009.08.038. Epub 2009 Aug 21.

PMID:
19762246
4.

SAR studies of 2-methoxyestradiol and development of its analogs as probes of anti-tumor mechanisms.

Ho A, Kim YE, Lee H, Cyrus K, Baek SH, Kim KB.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3383-7. Epub 2006 May 2.

PMID:
16650989
5.

Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on tubulin polymerization.

Edsall AB, Mohanakrishnan AK, Yang D, Fanwick PE, Hamel E, Hanson AD, Agoston GE, Cushman M.

J Med Chem. 2004 Oct 7;47(21):5126-39.

PMID:
15456256
6.

Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues.

Saha P, Descôteaux C, Brasseur K, Fortin S, Leblanc V, Parent S, Asselin E, Bérubé G.

Eur J Med Chem. 2012 Feb;48:385-90. doi: 10.1016/j.ejmech.2011.12.017. Epub 2011 Dec 17.

PMID:
22209414
7.

2-Methoxyestradiol and analogs as novel antiproliferative agents: analysis of three-dimensional quantitative structure-activity relationships for DNA synthesis inhibition and estrogen receptor binding.

Hughes RA, Harris T, Altmann E, McAllister D, Vlahos R, Robertson A, Cushman M, Wang Z, Stewart AG.

Mol Pharmacol. 2002 May;61(5):1053-69.

8.

Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.

Saha P, Fortin S, Leblanc V, Parent S, Asselin É, Bérubé G.

Steroids. 2012 Sep;77(11):1113-22. doi: 10.1016/j.steroids.2012.06.004. Epub 2012 Jul 16.

PMID:
22801351
9.
10.

Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs.

Rao PN, Cessac JW, Tinley TL, Mooberry SL.

Steroids. 2002 Dec;67(13-14):1079-89.

PMID:
12441194
11.

Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.

Edsall AB, Agoston GE, Treston AM, Plum SM, McClanahan RH, Lu TS, Song W, Cushman M.

J Med Chem. 2007 Dec 27;50(26):6700-5. Epub 2007 Dec 6.

PMID:
18052315
12.

beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.

Gökmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, Lavallee TM, Wang M, Guenther BD, Giannakakou P, Sledge GW Jr.

Cancer Res. 2005 Oct 15;65(20):9406-14.

13.

Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs.

Suwandi LS, Agoston GE, Shah JH, Hanson AD, Zhan XH, Lavallee TM, Treston AM.

Bioorg Med Chem Lett. 2009 Nov 15;19(22):6459-62. doi: 10.1016/j.bmcl.2009.09.009. Epub 2009 Sep 9.

PMID:
19782568
14.

A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents.

Leese MP, Hejaz HA, Mahon MF, Newman SP, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2005 Aug 11;48(16):5243-56.

PMID:
16078843
15.

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM.

Mol Cancer Ther. 2008 Jun;7(6):1472-82. doi: 10.1158/1535-7163.MCT-08-0107.

16.

Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.

Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2008 Mar 13;51(5):1295-308. doi: 10.1021/jm701319c. Epub 2008 Feb 9.

PMID:
18260615
18.

Synthesis and screening of N-alkyl hydroxamates for inhibition of cancer cell proliferation.

Stanger KJ, Sliva D, Jiang J, Krchnák V.

Comb Chem High Throughput Screen. 2006 Nov;9(9):651-61.

PMID:
17100571
19.

Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.

Jourdan F, Leese MP, Dohle W, Hamel E, Ferrandis E, Newman SP, Purohit A, Reed MJ, Potter BV.

J Med Chem. 2010 Apr 8;53(7):2942-51. doi: 10.1021/jm9018806.

PMID:
20225862
20.

Antiproliferative activity of withanolides against human breast cancer cell lines.

Machin RP, Veleiro AS, Nicotra VE, Oberti JC, M Padrón J.

J Nat Prod. 2010 May 28;73(5):966-8. doi: 10.1021/np9006734.

PMID:
20438092

Supplemental Content

Support Center